Insight Molecular Diagnostics Inc.
Customers
4
0 disclosed
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Dec 31, 2023
10-K filed 2024-04-16
Customers 4
Companies IMDX discloses as major customers, as a share of IMDX revenue. 0 active, 4 lapsed.
| Company | % of IMDX revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| Pharma Services Company A Non-SEC Pharma Services Company A |
47% | $706.4K | FY 2023-12-31 | +4.0pp | Lapsed Last seen 2023-12-31 |
10-K 2024-04-16 |
Pharma services - Company A 47 % 43 % Pharma Services Company A * 35 % | ||||||
| Pharma Services Company B Non-SEC Pharma Services Company B |
27% | $405.8K | FY 2023-12-31 | +13.0pp | Lapsed Last seen 2023-12-31 |
10-K 2024-04-16 |
Pharma services - Company B 27 % 14 % | ||||||
| Pharma Services Company C Non-SEC Pharma Services Company C |
11% | $165.3K | FY 2023-12-31 | ±0.0pp | Lapsed Last seen 2023-12-31 |
10-K 2024-04-16 |
Pharma services - Company C 11 % 11 % | ||||||
| Medicare Advantage for DetermaRx Non-SEC Medicare Advantage for DetermaRx |
Named | — | FY 2021-12-31 | — | Lapsed Last seen 2021-12-31 |
10-K 2022-03-11 |
Medicare Advantage for DetermaRx™ 65 % * | ||||||
Named as competitors
Companies this filer names as competitors.
Alerts are coming
Get an email when IMDX's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.